The Companys 13-valent pneumococcal conjugate vaccine.

announced today that has the United States Food and Drug Administration approved for issued Prevnar 13 , the Company’s 13-valent pneumococcal conjugate vaccine. Prevnar 13 is indicated for active immunization of children 6 weeks to 5 years for the prevention of invasive disease by 13 Streptococcus pneumoniae serotypes 1, 14 are caused, displayed, 19F and 23F. Prevnar 13 is also indicated for the prevention of otitis media by serotypes 4, caused 19F and 23F. No otitis media efficacy data for serotypes 1, 7F and 19A available.

The approval of Prevnar 13 means vaccine, which infants and young children in the United States have access to a pneumococcal conjugate vaccine, which provides protection against 13 serotypes, which can life-threatening illnesses life-threatening illnesses, says Emilio Emini, chief scientific officer, Vaccine Research, Pfizer Inc. Together, these 13 (1. For the majority of invasive pneumococcal disease in the United States In particular, serotype 19A is now the most common invasive disease-causing serotypes in young children. .Jew Medical valve. When we were to move with new technologies like our Trifecta valve, we are not just continued the heritage infused instilled from our mechanical valves, but well advanced innovation, best-in-class life-saving technologies. .. Units Medical is celebrating Its Two Millionth mechanical valve Implantable.

For years, Jew Medical works closely with physicians and institutional institutions around the world in order our extraordinary valve technology develop, said Frank J. Callaghan, president of St.